Drug General Information (ID: D0288)
  Drug Name
Cefpodoxime
  Drug Type Small molecule
  Drug Synonymous
CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    Click to Show/Hide
  Disease Class 1A00-1C4Z: Bacterial infection
  Therapeutic Class Antibiotics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C15H17N5O6S2
  InChI 1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
  InChIKey WYUSVOMTXWRGEK-HBWVYFAYSA-N
  Canonical SMILES COCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
  External Link
Pubchem ID 6335986
CAS Number 80210-62-4
CHEBI ID 3504
TTD ID D0W6CA
INTEDE ID DR2661
VARIDT ID DR00974

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM003  Affected organization distribution
AM005  Affected excretion pathways
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM002  Altered intestinal flora
BM003  Complex formation
BM005  Altered gastric pH
BM014  Interference of cell/tissue uptake
BM028  Competitive inhibition of renal tubular secretion
BM031  Increased renal excretion (Unspecific)
BM050  Increased risk of bleeding
BM072  Increased risk of nephrotoxicity
BM100  Antagonize the effect of vaccine/toxoid
BM107  Attenuated pharmacological effects (Unspecific)
  Relation Graph
 Full list of drugs interacting with Cefpodoxime
      Affected gastrointestinal absorption
   Altered intestinal flora Drug Num:  2
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D1094
 
Mycophenolate mofetil
 
C23H31NO7
 
5281078 
Moderate    Inter Info   
[71], [72]
D1095
 
Mycophenolic acid
 
C17H20O6
 
446541 
Moderate    Inter Info   
[71], [72]
   Complex formation Drug Num:  1
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D1369
 
Quinapril
 
C25H30N2O5
 
54892 
Moderate    Inter Info   
[1], [102]
   Altered gastric pH Drug Num:  19
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0049
 
Aluminum hydroxide
 
AlH3O3
 
10176082 
Moderate    Inter Info   
[56], [57], [58], [59]
D0236
 
Calcium carbonate
 
CCaO3
 
10112 
Moderate    Inter Info   
[56], [57], [58], [59]
D0458
 
Dexlansoprazole
 
C16H14F3N3O2S
 
9578005 
Moderate    Inter Info   
[56], [57], [58], [59]
D0967
 
Magaldrate
 
AlHMgO5S+2
 
3086011 
Moderate    Inter Info   
[56], [57], [58], [59]
D0968
 
Magnesium carbonate
 
CMgO3
 
11029 
Moderate    Inter Info   
[56], [57], [58], [59]
D0973
 
Magnesium hydroxide
 
H2MgO2
 
14791 
Moderate    Inter Info   
[56], [57], [58], [59]
D1483
 
Sodium citrate
 
C6H5Na3O7
 
6224 
Moderate    Inter Info   
[56], [57], [58], [59]
D0337
 
Cimetidine
 
C10H16N6S
 
2756 
Moderate    Inter Info   
[56], [57], [58], [59]
D0483
 
Didanosine
 
C10H12N4O3
 
135398739 
Moderate    Inter Info   
[56], [57], [58], [59]
D0603
 
Esomeprazole
 
C17H19N3O3S
 
9568614 
Moderate    Inter Info   
[56], [57], [58], [59]
D0636
 
Famotidine
 
C8H15N7O2S3
 
5702160 
Moderate    Inter Info   
[56], [57], [58], [59]
D0892
 
Lansoprazole
 
C16H14F3N3O2S
 
3883 
Moderate    Inter Info   
[56], [57], [58], [59]
D1151
 
Nizatidine
 
C12H21N5O2S2
 
3033637 
Moderate    Inter Info   
[56], [57], [58], [59]
D1179
 
Omeprazole
 
C17H19N3O3S
 
4594 
Moderate    Inter Info   
[56], [57], [58], [59]
D1222
 
Pantoprazole
 
C16H15F2N3O4S
 
4679 
Moderate    Inter Info   
[56], [57], [58], [59]
D1373
 
Rabeprazole
 
C18H21N3O3S
 
5029 
Moderate    Inter Info   
[56], [57], [58], [59]
D1381
 
Ranitidine
 
C13H22N4O3S
 
3001055 
Moderate    Inter Info   
[56], [57], [58], [59]
D1382
 
Ranitidine (bismuth citrate)
 
C13H22N4O3S
 
3001055 
Moderate    Inter Info   
[57], [58], [59]
D1480
 
Sodium bicarbonate
 
CHNaO3
 
516892 
Moderate    Inter Info   
[56], [57], [58], [59]
      Affected organization distribution
   Interference of cell/tissue uptake Drug Num:  1
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D1817
 
Indium In-111 oxyquinoline
 
C27H18InN3O3
 
16685037 
Moderate    Inter Info   
[60]
      Affected excretion pathways
   Competitive inhibition of renal tubular secretion Drug Num:  3
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0576
 
Entecavir
 
C12H15N5O3
 
135398508 
Moderate    Inter Info   
[67]
D1241
 
Pemetrexed
 
C20H21N5O6
 
135410875 
Moderate    Inter Info   
[73]
D1341
 
Probenecid
 
C13H19NO4S
 
4911 
Moderate    Inter Info   
[74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93], [94], [95], [96], [97], [98], [99], [100], [101]
   Increased renal excretion (Unspecific) Drug Num:  3
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0217
 
Bumetanide
 
C17H20N2O5S
 
2471 
Moderate    Inter Info   
[48], [49], [50], [51], [52], [53], [54], [55]
D0613
 
Etacrynic acid
 
C13H12Cl2O4
 
3278 
Moderate    Inter Info   
[48], [49], [52]
D1611
 
Torasemide
 
C16H20N4O3S
 
41781 
Moderate    Inter Info   
[48], [49], [52]
      Pharmacodynamic additive effects
   Increased risk of bleeding Drug Num:  3
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0087
 
Anisindione
 
C16H12O3
 
2197 
Moderate    Inter Info   
[44], [45], [46]
D0481
 
Dicoumarol
 
C19H12O6
 
54676038 
Moderate    Inter Info   
[44], [45], [46]
D1711
 
Warfarin
 
C19H16O4
 
54678486 
Moderate    Inter Info   
[44], [45], [46]
   Increased risk of nephrotoxicity Drug Num:  10
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0056
 
Amikacin
 
C22H43N5O13
 
37768 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
D0057
 
Amikacin (liposome)
 
C22H43N5O13
 
37768 
Moderate    Inter Info   
[14], [22], [43]
D0724
 
Givosiran
 
C78H139N11O30
 
119058042 
Moderate    Inter Info   
[11], [1]
D1304
 
Plazomicin
 
C25H48N6O10
 
42613186 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
D0718
 
Gentamicin
 
C21H43N5O7
 
3467 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
D0876
 
Kanamycin
 
C18H36N4O11
 
6032 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
D1126
 
Netilmicin
 
C21H41N5O7
 
441306 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
D1138
 
Nimodipine
 
C21H26N2O7
 
4497 
Moderate    Inter Info   
[11], [1]
D1507
 
Streptomycin
 
C21H39N7O12
 
19649 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
D1597
 
Tobramycin
 
C18H37N5O9
 
36294 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43]
      Pharmacodynamic antagonistic effects
   Antagonize the effect of vaccine/toxoid Drug Num:  2
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D1914
 
Typhoid vaccine (live)
 
NA
 
NA
Major    Inter Info   
[1], [2], [3]
D1693
 
Vibrio cholerae CVD 103-HgR strain live antigen (live)
 
NA
 
NA
Major    Inter Info   
[4]
   Attenuated pharmacological effects (Unspecific) Drug Num:  5
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0145
 
Balsalazide
 
C17H15N3O6
 
54585 
Moderate    Inter Info   
[47]
D1287
 
Picosulfuric acid
 
C18H15NO8S2
 
5243 
Moderate    Inter Info   
[61], [62], [63]
D0313
 
Chloramphenicol
 
C11H12Cl2N2O5
 
5959 
Moderate    Inter Info   
[64], [65], [66]
D0619
 
Ethinylestradiol
 
C20H24O2
 
5991 
Moderate    Inter Info   
[68], [69], [70]
D1011
 
Mestranol
 
C21H26O2
 
6291 
Moderate    Inter Info   
[68], [69], [70]
References
1 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2 UK government "Typhoid.".
3 American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association (1994).
4 Product Information. Vaxchora (cholera vaccine, live). PaxVax, Miami, FL.
5 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
6 Aronoff GR, Brier RA, Sloan RS, Brier ME "Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990): 1139-42. [PMID: 2203304]
7 Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA "Lack of pharmacokinetic interaction between cefepime and amikacin in humans." Antimicrob Agents Chemother 36 (1992): 1382-6. [PMID: 1510431]
8 Bobrow SN, Jaffe E, Young RC "Anuria and acute tubular necrosis associated with gentamicin and cephalothin." JAMA 222 (1972): 1546-7. [PMID: 4678426]
9 Cabanillas F, Burgos RC, Rodriguez C, Baldizon C "Nephrotoxicity of combined cephalothin-gentamicin regimen." Arch Intern Med 135 (1975): 850-2. [PMID: 1130930]
10 Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR "Nephrotoxicity associated with cephalothin administration." Arch Intern Med 135 (1975): 797-801. [PMID: 1130924]
11 Cerner Multum, Inc. "Australian Product Information.".
12 Cockram CS, Richards P, Bax RP "The safety of cefuroxime and gentamicin in patients with reduced renal function." Curr Med Res Opin 6 (1980): 398-403. [PMID: 7363640]
13 Dellinger P, Murphy T, Barza M, et al "Effect of cephalothin on renal cortical concentrations of gentamicin in rats." Antimicrob Agents Chemother 9 (1976): 587-8. [PMID: 1267436]
14 Engle JE, Drago J, Carlin B, Schoolwerth AC "Letter: Reversible acute renal failure after cephalothin." Ann Intern Med 83 (1975): 232-3. [PMID: 1147461]
15 Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2. [PMID: 984759]
16 Fanning WL, Gump D, Jick H "Gentamicin- and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2. [PMID: 984759]
17 Fillastre JP, Laumonier R, Humbert G, et al "Acute renal failure associated with combined gentamicin and cephalothin therapy." Br Med J 2 (1973): 396-7. [PMID: 4703097]
18 Foord RD "Cephaloridine, cephalothin and the kidney." J Antimicrob Chemother 1 (1975): 119-33. [PMID: 1201976]
19 Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS "Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies." Cancer Treat Rep 62 (1978): 693-8. [PMID: 657154]
20 Gurwich EL, Sula J, Hoy RH "Gentamicin-cephalothin drug reaction." Am J Hosp Pharm 35 (1978): 1402-3. [PMID: 707512]
21 Hansen MM, Kaaber K "Nephrotoxicity in combined cephalothin and gentamicin therapy." Acta Med Scand 201 (1977): 463-7. [PMID: 899868]
22 Kabins SA, Cohen S "Cephalothin serum levels in the azotemic patient." Antimicrob Agents Chemother 10 (1964): 207-14. [PMID: 14287932]
23 Klastersky J, Hensgens C, Debusscher L "Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin." Antimicrob Agents Chemother 7 (1975): 640-5. [PMID: 1096809]
24 Kleinknecht D, Ganeval D, Droz D "Acute renal failure after high doses of gentamicin and cephalothin." Lancet 05/19/73 (1973): 1129. [PMID: 4122055]
25 Kleinknecht D, Ganeval D, Droz D "Acute renal failure after high doses of gentamicin and cephalothin." Lancet 1 (1973): 1129. [PMID: 4122055]
26 Krcmery V, Fuchsberger P, Gocar M, et al "Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients." Chemotherapy 37 (1991): 287-91. [PMID: 1790727]
27 Pasternak DP, Stephens BG "Reversible nephrotoxicity associated with cephalothin therapy." Arch Intern Med 135 (1975): 599-602. [PMID: 1138675]
28 Pickering MJ, Spooner GR, Quesada A, de Cade JR "Declining renal function associated with administration of cephalothin." South Med J 63 (1970): 426-8. [PMID: 5437593]
29 Plager JE "Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease." Cancer 37 (1976): 1937-43. [PMID: 1260696]
30 Product Information. Arikayce (amikacin liposome). Insmed Incorporated, Bridgewater, NJ.
31 Product Information. Mycifradin (neomycin). Emerson Laboratories, Texarkana, TX.
32 Renal failure in combined gentamicin and cephalothin therapy. Br Med J 2 (1973): 776-7. [PMID: 4718331]
33 Rodjer S, Alestig K, Bergmark J, et al "Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects." J Antimicrob Chemother 20 (1987): 109-16. [PMID: 3305460]
34 Sanders WE, Jr Johnson JE, 3d Taggart JG "Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses." N Engl J Med 290 (1974): 424-9. [PMID: 4811017]
35 Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982): 721-6. [PMID: 7103453]
36 Schultze RG, Winters RE, Kauffman H "Possible nephrotoxicity of gentamicin." J Infect Dis 124 (1971): s145-7. [PMID: 5126240]
37 Schwartz JH, Schein P "Fanconi syndrome associated with cephalothin and gentamicin therapy." Cancer 41 (1978): 769-72. [PMID: 343914]
38 Tobias JS, Whitehouse JM, Wrigley PF "Letter: Severe renal dysfunction after tobramycin/cephalothin therapy." Lancet 1 (1976): 425. [PMID: 55686]
39 Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J "Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G." J Antimicrob Chemother 12 (1983): 641-5. [PMID: 6363382]
40 Tvedegaard E "Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure." Lancet 2 (1976): 581. [PMID: 60663]
41 Wade J, Smith C, Petty B, et al "Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin." Curr Chem 2 (1978): 971-2.
42 Wade JC, Smith CR, Petty BG, et al "Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside." Lancet 2 (1978): 604-6. [PMID: 80528]
43 Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K "Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients." J Clin Pharmacol 22 (1982): 403-9. [PMID: 7130429]
44 Product Information. Suprax (cefixime). Lupin Pharmaceuticals Inc, Baltimore, MD.
45 Wood T, Johnson K, Naylor S, Weinshilboum R "Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia." Drug Metab Dispos 30 (2002): 1123-1128
46 Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976): 91-3
47 Product Information. Colazal (balsalazide) Salix Pharmaceuticals, Palo Alto, CA.
48 Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
49 Dodds MG, Foord RD "Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine." Br J Pharmacol 40 (1970): 227-36. [PMID: 5492895]
50 Korn A, Eichler HG, Gasic S "A drug interaction study of ceftriaxone and frusemide in healthy volunteers." Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4. [PMID: 3733274]
51 Lawson DH, Macadam RF, Singh H, et al "Effect of furosemide on antibiotic-induced renal damage in rats." J Infect Dis 126 (1972): 593-600. [PMID: 4664116]
52 Norrby R, Stenqvist K, Elgefors B "Interaction between cephaloridine and furosemide in man." Scand J Infect Dis 8 (1976): 209-12. [PMID: 968459]
53 Simpson IJ "Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine." N Z Med J 74 (1971): 312-5. [PMID: 5289757]
54 Tilstone WJ, Semple PF, Lawson DH, Boyle JA "Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin." Clin Pharmacol Ther 22 (1977): 389-94. [PMID: 902451]
55 Trollfors B, Norrby R, Kristianson K, Nilsson NJ "Effects on renal function of treatment with cefoxitin alone or in combination with furosemide." Scand J Infect Dis 13 (1978): 73-7. [PMID: 356182]
56 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
57 Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
58 Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
59 Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
60 Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111). GE Healthcare, Princeton, NJ.
61 Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate). Ferring Pharmaceuticals Inc, Tarrytown, NY.
62 MHRA. Medicines and Healthcare Regulatory Agency (general site Reference).
63 Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate). Ferring Pharmaceuticals Inc, Tarrytown, NY.
64 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
65 Asmar BI, Prainito M, Dajani AS "Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone." Antimicrob Agents Chemother 32 (1988): 1375-8
66 Brown TH, Alford RH "Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae." Antimicrob Agents Chemother 25 (1984): 405-7
67 Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
68 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
69 Barnett ML "Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration." J Periodontol 56 (1985): 18-20. [PMID: 3882930]
70 King VJ "OC failure rates and oral antibiotics." J Fam Pract 45 (1997): 104-5. [PMID: 9267366]
71 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
72 Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
73 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
74 Brown G, Zemcov SJ, Clarke AM "Effect of probenecid on cefazolin serum concentrations." J Antimicrob Chemother 31 (1993): 1009-11. [PMID: 8360120]
75 Brown GR "Cephalosporin-probenecid drug interactions." Clin Pharmacokinet 24 (1993): 289-300. [PMID: 8491057]
76 Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD "Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels." J Antimicrob Chemother 40 (1997): 903-6. [PMID: 9462447]
77 Griffith RS, Black HR, Brier GL, Wolny JD "Effect of probenecid on the blood levels and urinary excretion of cefamandole." Antimicrob Agents Chemother 11 (1977): 809-12. [PMID: 879735]
78 Ings RM, Reeves DS, White LO, et al "The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination." J Pharmacokinet Biopharm 13 (1985): 121-42. [PMID: 4057054]
79 Kercsmar CM, Stern RC, Reed MD, et al "Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response." J Antimicrob Chemother 12 (1983): 289-95. [PMID: 6352634]
80 Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ "Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination." Antimicrob Agents Chemother 33 (1989): 356-61. [PMID: 2729930]
81 DiPiro JT, Welage LS, Levine BA, et al. Single-dose cefmetazole versus multiple dose cefoxitin for prophylaxis in abdominal surgery.?J Antimicrob Chemother. 1989;23 Suppl D:71-77. [PMID: 2722725]
82 LeBel M, Paone RP, Lewis GP "Effect of probenecid on the pharmacokinetics of ceftizoxime." J Antimicrob Chemother 12 (1983): 147-55. [PMID: 6311785]
83 Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W "Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime." Antimicrob Agents Chemother 20 (1981): 567-75. [PMID: 6275776]
84 Marino EL, Dominguez-Gil A "The pharmacokinetics of cefadroxil associated with probenecid." Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8. [PMID: 6795136]
85 LeBel M, Paone RP, Lewis GP. Effect of probenecid on the pharmacokinetics of ceftizoxime.?J Antimicrob Chemother. 1983;12(2):147-155. [PMID: 6311785]
86 Mischler TW, Sugerman AA, Willard DA, et al "Influence of probenecid and food on the bioavailability of cephradine in normal male subjects." J Clin Pharmacol 14 (1974): 604-11. [PMID: 4436447]
87 Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ "Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting." Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7. [PMID: 7889965]
88 Pitkin D, Dubb J, Actor P, et al "Kinetics and renal handling of cefonicid." Clin Pharmacol Ther 30 (1981): 587-93. [PMID: 7297018]
89 Product Information. Ceftin (cefuroxime). Glaxo Wellcome, Research Triangle Park, NC.
90 Product Information. Fortaz (ceftazidime). Glaxo Wellcome, Research Triangle Park, NC.
91 Product Information. Omnicef (cefdinir). Parke-Davis, Morris Plains, NJ.
92 Product Information. Rocephin (ceftriaxone). Roche Laboratories, Nutley, NJ.
93 Product Information. Tazicef (ceftazidime). SmithKline Beecham, Philadelphia, PA.
94 Product Information. Vantin (cefpodoxime proxetil). Pharmacia and Upjohn, Kalamazoo, MI.
95 Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP "The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers." Br J Clin Pharmacol 11 (1981): 353-9. [PMID: 7259928]
96 Santoro J, Agarwal BN, Martinelli R, et al "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978): 951-4. [PMID: 677862]
97 Shukla UA, Pittman KA, Barbhaiya RH "Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers." J Clin Pharmacol 32 (1992): 725-31. [PMID: 1487562]
98 Spina SP, Dillon EC "Effect of chronic probenecid therapy on cefazolin serum concentrations." Ann Pharmacother 37 (2003): 621-4. [PMID: 12708933]
99 Stoeckel K, Trueb V, Dubach UC, McNamara PJ "Effect of probenecid on the elimination and protein binding of ceftriaxone." Eur J Clin Pharmacol 34 (1988): 151-6. [PMID: 3383987]
100 Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB "Effect of orally administered probenecid on the pharmacokinetics of cefoxitin." Antimicrob Agents Chemother 17 (1980): 847-55. [PMID: 7396472]
101 Welling PG, Dean S, Selen A, et al "Probenecid: an unexplained effect on cephalosporin pharmacology." Br J Clin Pharmacol 8 (1979): 491-5. [PMID: 508557]
102 Multum Information Services, Inc. Expert Review Panel.